Video Library

Highlights of Expert Commentary of OFS
In this final video, Polly Niravath, MD, Abbey Kaler, APRN, FNP-C, CMSRN, and Emily Beard, RN, BSN, OCN, CBCN, CG, discuss the clinical features of premenopausal women with breast cancer who may be suitable for treatment with ovarian function suppression (OFS) therapy, effective use of OFS therapy, and relevant navigation strategies used to address the potential challenges associated with OFS treatment.
Managing Clinical and Psychosocial Impacts of OFS
Hear expert commentary on ovarian function suppression (OFS) side effect management, including strategies used to address psychosocial challenges affecting premenopausal breast cancer patients undergoing OFS.
Setting Patient Expectations of OFS Treatment
Listen as a nurse navigator discusses ovarian function suppression (OFS) and the subsequent impact of OFS on premenopausal women with breast cancer.
Fertility Preservation and Benefits of OFS
Polly Niravath, MD, discusses fertility preservation in premenopausal women with breast cancer who are undergoing ovarian function suppression (OFS) treatment.
Real-world Outcomes Following Initiation of Abemaciclib in Patients With Brain Metastases Secondary to HR+/HER2- Metastatic Breast Cancer
Dr Rugo of the University of California San Francisco Comprehensive Cancer Center reports on the outcomes of a retrospective study of patients with metastatic breast cancer and brain metastases treated with abemaciclib.
Primary Analysis of HER2CLIMB-02: Addition of Tucatinib to Trastuzumab Emtansine in Previously Treated Patients with HER2-Positive Metastatic Breast Cancer
Dr Tolaney of Dana-Farber Cancer Institute reviews data on HER2CLIMB-02 and contributes future considerations of tucatinib in the metastatic HER2-positive breast cancer setting.
INAVO120 Phase III Study: Treatment of Patients With PIK3CA-mutant, HR+/HER2- Locally Advanced or Metastatic Breast Cancer With Invavolisib in Combination With Palbociclib and Fulvestrant
Dr Rugo of the University of California San Francisco Comprehensive Cancer Center provides her insights on the practical aspects of the reported results of the INAVO120 phase 3 study.
Abemaciclib and NSAI for 1L Treatment of HR+/HER2- Advanced Breast Cancer: Long-term Survival Data Reported
Dr Tolaney of Dana-Farber Cancer Institute discusses her perspectives on the clinically meaningful overall survival outcomes of abemaciclib added to a nonsteroidal aromatase inhibitor as initial therapy in patients with HR+/HER2- advanced breast cancer.
Evolving Adjuvant Treatment Landscape for HR+/HER2- Early Breast Cancer
This first installment observes how the adjuvant treatment landscape has evolved for patients with HR+/HER2- early breast cancer, including discussion on the monarchE study.
New Developments on Prognostic Markers for Patients With Early Breast Cancer
This second installment discusses data presented at ESMO 2023 on prognostic markers for patients with early breast cancer, highlighting data from the monarchE study, the NATALEE study, and the BCIRG 001 and 005 trials.
Recent Clinical Trials of Neoadjuvant Immunotherapy in Breast Cancer
This third installment observes data presented at ESMO 2023 on neoadjuvant immunotherapy in breast cancer, with a discussion of the KEYNOTE-522 study, NeoTRIP study, KEYNOTE-756 study, and the EMBER-2 study.
Educating on HER2-Low mBC
In this inaugural video, the panel provides peer-to-peer perspectives on educating the care team and patients on the new classification of HER2-low mBC.
Page 1 of 10
Results 1 - 12 of 118

Subscribe Today!

To sign up for our print publication or e-newsletter, please enter your contact information below.

I'd like to receive:

  • First Name *
    Last Name *
    Profession or Role
    Primary Specialty or Disease State